FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. (Nasdaq: CTKB) is taking steps to ensure critical scientific research can continue. Joining the International Society for Advancement of Cytometry’s (ISAC) mission to advance global availability and adoption of cytometry technology and empower scientists, Cytek has launched a two-part research support initiative to make cell analysis more accessible.

ISAC President Jessica P. Houston commended these initiatives. “Cytek’s commitment to expanding access to advanced cytometry is a vital contribution to global public health. By supporting under-resourced labs, they’re helping ensure that essential research can continue – regardless of geography or funding. I applaud this meaningful step toward greater scientific equity.”

As the first phase of this initiative, Cytek is awarding a three-laser Cytek Northern Lights™ flow cytometer. This easy-to-use, flexible, and affordable full spectrum flow cytometer incorporates Cytek’s powerful Full Spectrum Profiling™ (FSP^®) technology, enabling a wide array of assays on one instrument. The Cytek Northern Lights™ system delivers high-quality data quickly, making advanced performance attainable for everyday research applications.

“What sets Cytek apart is not just the instruments we build, but how we engage with the scientific community,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “Our employees share a passion for advancing discovery, and that inspires us to support research through initiatives like this. Together, we are helping shape an industry where innovation is measured not only by patents or features but by the real impact on science worldwide.”

In the second phase of the initiative, Cytek plans to launch a grant program to fund eligible research projects, with applications assessed through a transparent, merit-based process overseen by the company’s scientific advisory board. The grant program is expected to debut in conjunction with CYTO 2026, with full details to be shared at that time.

These initiatives build on an ongoing collaboration between Cytek and ISAC to expand access to advanced cytometry tools worldwide. Earlier this year, the organizations partnered to donate a Cytek Northern Lights™ flow cytometer to the Laboratory of Molecular Biology and Cytogenetics at Hospital Dr. Arturo Oñativia in Salta, Argentina. With support from both ISAC and Cytek, the instrument is enabling high-parameter immune monitoring and translational research, strengthening scientific capabilities in the region. The donation exemplifies how collaboration can empower scientists in underserved communities and advance the field of cytometry globally.

Cytek is committed to democratizing access to flow cytometry, empowering every lab, regardless of budget, size, or location, with the tools and support to unlock cellular insights that drive progress in health, science, and society.

“By pairing world-class instrumentation with community engagement and support programs, Cytek is helping to ensure that the benefits of innovation reach the entire scientific community,” Jiang added. “We are committed to supporting research that advances science for everyone.”

To enter for a chance to win the Cytek Northern Lights™ three-laser system, please visit https://cytekbio.com/pages/expanding-access.¹

For more information, please visit https://cytekbio.com/.

About the International Society for Advancement of Cytometry (ISAC)
The International Society for Advancement of Cytometry (ISAC) is a global scientific society with a mission to foster an inclusive, multidisciplinary, international community in the field of single-cell analysis. Focusing on flow and image cytometry, automated microscopy, and high-content screening, ISAC champions technological innovation and the development of professionals in these domains. With a vision centered on advancing cytometry, ISAC addresses key challenges in single-bioparticle analysis. As a collaborative hub, ISAC facilitates the exchange of cutting-edge ideas and educational opportunities, uniting academicians, industry professionals, researchers, and students. To discover more about ISAC’s contributions to the world of cytometry or to explore the benefits of membership, please visit www.isac-net.org.

About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP^®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis^® and Guava^® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek’s future initiatives to expand access to advanced cytometry tools worldwide. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q filed on August 6, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s as of any date subsequent to the date of this press release.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com

¹ No purchase necessary to enter or win. The instrument award is open only to institutions, organizations, and business entities that are eligible to participate through an authorized representative over the age of 18 who is a legal resident of the United States or Canada. Please read the Official Rules and Privacy Notice for more information.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c39ad800-c0ca-41fd-8cf0-f5e80c4156e6